Grifols, S.A. - American Depositary Shares (GRFS) Covered Calls

Grifols, S.A. is engaged in the research, development, manufacture and marketing of plasma derivatives, IV therapy, enteral nutrition, diagnostic systems and medical materials.

You can sell covered calls on Grifols, S.A. - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GRFS (prices last updated Thu 4:16 PM ET):

Grifols, S.A. - American Depositary Shares (GRFS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
6.27 -0.12 6.02 6.38 1.0M - 0.0
Covered Calls For Grifols, S.A. - American Depositary Shares (GRFS)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
May 17 6 0.75 5.63 6.6% 105%
Jun 21 6 0.85 5.53 8.5% 53.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through four segments: Bioessence, Hospital, Diagnostic and Raw Materials. The Bioessence segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by Group companies earmarked for hospital pharmacy. The Diagnostic segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. Grifols was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.